The HepG2 cell line has been used extensively to study the synthesis and secretion of apolipoprotein (apo) B. In this study, we tested whether gene-targeting techniques can be used to inactivate one of the apo B alleles in HepG2 cells by homologous recombination using a transfected gene-targeting vector. Our vector contained exons 1-7 of the apo B gene, in which exon 2 was interrupted by a promoterless neomycin resistance (neor) gene. The recombination of this vector with the cognate gene would inactivate an apo B allele and enable the apo B promoter to activate the transcription of the neo' gene. To detect the rare homologous recombinant clone, we developed a novel solid phase RIA that uses the apo B-specific monoclonal antibody MB19 to analyze the apo B secreted by G418-resistant (G418r) clones. Antibody MB19 detects a two-allele genetic polymorphism in apo B by binding to the apo B allotypes MB191 and MB192 with high and low affinity, respectively.
Introduction
Apo B 100 is secreted by the liver as a component ofVLDL ( 1), a portion of which are then metabolized in the circulation to the denser, cholesterol-enriched LDL. Apo B 100 is virtually the sole protein component of LDL, and plasma apo B100 levels correlate directly with the risk of developing atherosclerotic coronary heart disease (2) . Plasma apo B1100 levels are determined by a steady state resulting from the rate ofsynthesis and secretion of apo B 100 from the liver and from the rate of apo B100 clearance from the plasma. The human hepatoma cell line HepG2 has been used extensively as a cell culture model to study the synthesis and secretion of apo B100 from liver cells (3, 4) .
To further understand apo B synthesis and secretion, it would be useful to be able to introduce specific mutations into the apo B gene in HepG2 cells. This is now possible in principle, using the recently developed techniques of gene targeting. These techniques have made it possible to inactivate genes or to introduce subtle mutations into genes in embryonic stem cells or in permanent cell lines (5) . To inactivate a gene, the DNA vector used contains a fragment ofthe gene ofinterest, in which one of the exons is interrupted by a selection marker coding for drug resistance. The homologous recombination of the vector with the cognate gene in a cultured cell inactivates one allele ofthe gene and results in a drug-resistant phenotype.
In this study, we tested whether gene-targeting techniques can be used to inactivate an apo B allele in HepG2 cells. The targeting strategy that we chose used a targeting vector containing a promoterless neomycin resistance (n eor) gene as a selection marker. The use of a promoterless neor gene in the vector limits viable cell clones to those in which the transfected vector recombines near an active cellular promoter; this strategy is applicable when the gene ofinterest is expressed in the cell line, as apo B is in HepG2 cells, and has been reported to enrich greatly the population of selected cell clones for homologous recombination (6, 7) .
Despite the use of various enrichment strategies, identifying a targeted clone is often laborious, requiring genomic DNA analysis of hundreds or thousands of individual clones by Southern blotting or the polymerase chain reaction (PCR). To detect the rare homologous recombinant clone in this study, we developed a novel solid phase RIA using the apo B-specific monoclonal antibody MB 19 (6) . Our vector, -10 kb long, contained three segments: a 5' 564-bp segment of the human apo B gene containing exon 1, intron 1, and a portion of exon 2; a middle segment containing a promoterless neor gene either with or without a poly(A) signal; and an 8.3-kb 3' apo B segment extending from intron 2 to intron 7 (Fig. 1) . To construct the poly(A)-vector, four DNA fragments were inserted into the polylinker ofpBIISK (Stratagene Inc., La Jolla, CA). First, a BglII-NruI (1083-bp) fragment [neor/ poly(A)-] from pSV2Neo was inserted into the BamHI and SmaI sites of pBIISK. Second, a 169-bp fragment of the apo B gene extending from just 3' of the apo B promoter (-15 relative to the transcriptional start site) to the middle ofexon 1 was enzymatically amplified from the human apo B clone X5c (8) and inserted into the XbaI and SpeI sites of pBIISK. Third, a 410-bp fragment ofthe apo B gene extending from the middle of exon I to exon 2 (apo B cDNA nucleotide 245) was amplified from XSc and inserted into the Spel site of pBIISK. The amplification oligonucleotides that we used for the 169-bp and 41 0-bp fragments were designed to eliminate the ATG translation initiation codon in exon 1 and two ATGs in exon 2. The ATGs were eliminated to prevent translation from beginning at these sites in a targeted cell. Finally, an 8.3-kb AsuII-KpnI fragment of XSc extending from intron 2 to intron 7 was inserted into the Clal and KpnI sites of the vector. Before this final ligation, a lone SacII site within the AsuII-KpnI fragment was eliminated so that it would be possible to linearize the vector at the polylinker SacIl site. A similar vector in which the neor gene had a polyadenylation signal [neor/poly(A)+] was also constructed. All cloning steps for this vector were the same as those described above except that the BglII/BamHI fragment of pSV2Neo was inserted into the BamHI site of pBIISK.
Tissue cultures and electroporations. HepG2 cells were obtained from the American Type Culture Collection (Rockville, MD) and cultured in minimum essential medium supplemented with 10% fetal bovine serum, 1% nonessential amino acids, and 1% sodium pyruvate. For the electroporations, -20 ,g of DNA vector were digested with SacII and KpnI (releasing the plasmid sequences), ethanol precipitated, and resuspended in 20 ,l of Tris-EDTA. Next, HepG2 cells were harvested by trypsinization from 80% confluent T-150 flasks, centrifuged at 200 g for 5 min, and resuspended in calcium-and magnesiumfree PBS, pH 7. The DNA was then transfected into 2 X 107 HepG2 cells (0.8 ml) by electroporation using a 250-V, 500-MLF pulse from a Gene Pulser (Bio-Rad Labs.-Chem.-Div., Richmond, CA). After 5 min, the cells were plated onto two 150-mm dishes. Selection with G418 (800 Mg/ml) was begun 24-48 h after the electroporation. After 3-4 wks, G4 18r colonies were transferred to 96-well culture plates for RIA screening.
RIA screening. A double label, solid phase RIA was developed to detect G41 8-resistant (G4 18') HepG2 clones that contained an inactivated apo B allele. The RIA was based on the use of the apo B-specific monoclonal antibody MB 19, which detects a two-allele genetic polymorphism in human apo B (9); antibody MBl9 binds to the apo B allotypes MB 19, and MB 192 with high and low affinity, respectively.
The MBl9 immunochemical polymorphism is associated with a C T transition in exon 4 of the apo B gene (apo B cDNA nucleotide 421 ), which results in a Thr -. Ile substitution at apo B amino acid 71 (10) . Previous studies have shown that HepG2 cells are trisomic for chromosome 2 (1 1 ), where the apo B gene is located ( 12) . We confirmed this finding by karyotyping several HepG2 clones. We next examined the MB 19 phenotype of the apo B secreted by HepG2 cells in competitive assays using antibody MB19 (9) and determined that HepG2 cells have three functioning apo B alleles: one MB 19, allele and two MB 192 alleles (see Fig. 2 B) . The successful inactivation of an apo B allele would therefore result in a change in the MB19 phenotype of the secreted apo B from 1/2/2 to either 1/2 or 2/2.
For the RIA, Dynatech Immulon 1 96-well plates (Fisher Scientific
Co., Pittsburgh, PA) were coated for 2 h with 50 Ml of PBS containing 1 /ig of the apo B-specific monoclonal antibody MB47/ml (epitope between apo B100 amino acids 3429 and 3523 [13] For Southern blotting, -10yIg ofgenomic DNA was digested with SphI, ApaLI, or HindIII-KpnI, separated on a 0.8% agarose gel, and transferred to a nylon membrane (Zetaprobe; Bio-Rad). The membrane was probed with a 32P-labeled HindIII-Stul apo B fragment located in the apo B promoter region outside the vector sequences (apo B nucleotides -1800 to -639) (Fig. 1 ).
Isolation and characterization oflipoproteins. Serum-free medium was placed on HepG2 cells for 24 h, and samples were collected and concentrated on Centriflo membrane cones (Amicon Corp., Danvers, MA). The size of the secreted apo B-containing lipoprotein particles was assessed by nondenaturing polyacrylamide gradient gel electrophoresis and Western blotting as described previously (17) . For electron microscopy, aliquots of the concentrated cell culture media were ultracentrifuged to obtain the d < 1.063 g/ml fraction. These lipoproteins were dialyzed against 150 mM NaCl and 1 mM EDTA, negatively stained, and examined by electron microscopy as described (18) . Lipoprotein sizes determined by electron microscopy were compared using an unpaired t test. identical to that of LDL isolated from an MB 192 (low-affinity) homozygote (Fig. 2 A) . The '25I-MBl9/'3 I-MB3 ratios for the remainder of the clones in this experiment varied by only 5-10%, demonstrating the reliability of the screening assay; no other clones had ratios approaching the MB 19 2/2 ( Fig. 2 A (Fig. 2 B) .
Results

Electroporations of 2 x I07
The PCR analysis of genomic DNA demonstrated an 869-bp control reaction amplification product that was detectable in each clone tested and an 865-bp target reaction amplification product that was detectable only in the potentially targeted clone and in a plasmid control (Fig. 3) clone was indeed targeted. Further supporting this conclusion, a more slowly migrating doublet band was present in the control reaction for each ofthe nontargeted clones, but was absent from the control reaction for the targeted clone. This doublet band is created by the formation of heteroduplex DNA during the amplification that is due to a 9-bp insertion/deletion polymorphism in the apo B signal peptide region ( 19 (Fig. 3 A) . Thus, the control PCR amplified only DNA from the two remaining nontargeted apo B alleles, which are both signal peptide insertion alleles, and no heteroduplex DNA was formed. The successful inactivation of an apo B allele was confirmed by Southern analysis of genomic DNA from the targeted clone (Fig. 4) A cell line producing such a truncated apo B would be useful in understanding the syndrome of hypobetalipoproteinemia. In this syndrome, apo B nonsense mutations result in the production of truncated apo Bs, which are invariably found in very low concentrations in the plasma. In many cases, the explanation for the low plasma apo B levels is unknown. For example, apo B3 1 is found at less than 5% ofnormal apo B 100 levels (30) , even though apo B3 1 lacks the region of the apo B molecule necessary for binding to LDL receptors. Transfection studies using apo B cDNA vectors containing strong viral promoters suggest that apo B3 1 and several other truncated apo Bs are secreted rapidly from cells (31 ) . These transfection studies do not address, however, whether nonsense mutations at the apo B gene locus result in diminished apo B synthesis rates; nonsense mutations in other genes are associated with low mRNA levels and low protein synthesis rates (32) (33) (34) . By introducing nonsense mutations into exon 26 of the apo B gene in HepG2 cells, the mRNA level and synthesis rate of a truncated apo B could be compared directly with those of apo B100.
The MB19 immunoassay could also be used to screen for the introduction of missense mutations into the apo B gene in HepG2 cells. Missense mutations could be introduced using the recently described "hit and run" gene-targeting strategy that has made it possible to introduce subtle mutations into a gene (35, 36) . Using gene-targeting methodology to express altered forms of apo B to study apo B structure and function might be easier than using apo B cDNA expression strategies. Introducing missense mutations into apo B 100 cDNA expression vectors (37) 
